Insider · CIK 0001769012
ARCH Venture Partners X, LLC
Files at NMRA (Neumora Therapeutics, Inc.), PRME (Prime Medicine, Inc.). First filing Aug 1, 2025, latest Oct 29, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
NMRA: Neumora Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 61Notable | Neumora Therapeutics, Inc. | $5.0M 1,915,700 shares | +46% | +337% from low-80% from high | |
| 57Moderate | Prime Medicine, Inc. | $10.0M 3,030,300 shares | +95% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 27, 2025 | NMRA Neumora Therapeutics, Inc. | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XII, L.P. | +1,915,700 | $2.61 | $5.0M | 6,046,907 | Oct 29, 2025 |
| Aug 1, 2025 | PRME Prime Medicine, Inc. | POpen-market purchase Common Stockindirect: By ARCH Venture Fund XII, L.P. | +3,030,300 | $3.30 | $10.0M | 6,230,300 | Aug 1, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.